Get startedLog in
    Picture of Newbury Pharmaceuticals AB logo

    NEWBRY — Newbury Pharmaceuticals AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    Consumer DefensivesHighly SpeculativeMicro CapMomentum Trap
    All News

    Brief: Newbury Pharmaceuticals Q4 EBITDA Loss Widens To SEK 3.6 Mln

    Picture of Newbury Pharmaceuticals AB logoNewbury Pharmaceuticals AB
    13/10/2022 10:47
    Oct 13 (Reuters) - Newbury Pharmaceuticals AB
 NEWBRY.ST :
    * YEAR-END REPORT SEPTEMBER 2021 – AUGUST 2022
    * Q4 NET REVENUE WAS 4 570 (2 097) TKR.
    * Q4 EBITDA WAS -3 626 (-1 822) TKR.

Source text for Eikon:  ID:nMFN648Z32 
Further company coverage:  NEWBRY.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))

    Recent news on Newbury Pharmaceuticals AB

    See all news